NCT02634294 2023-03-16
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2/3 Completed
Clinical Trials
10 trialsNCT01518517 2022-02-02
GRASPIVOTALL
ERYtech Pharma
Phase 2/3 Completed
NCT02910063 2021-01-13
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Amgen
Phase 2/3 Completed
NCT02673008 2020-02-25
MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Completed
NCT01197560 2019-11-25
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Celgene
Phase 2/3 Completed
NCT00749723 2018-07-20
HIT-REZ-2005
University Hospital, Bonn
Phase 2/3 Completed
NCT01458717 2018-05-02
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
Seoul National University Hospital
Phase 2/3 Completed
NCT01211938 2017-05-16
JANORL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2/3 Completed
NCT00070187 2013-10-17
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Children's Oncology Group
Phase 2/3 Completed
NCT01423032 2011-08-25
Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2/3 Completed